Novartis AG ADR (NVS)vsValneva SE ADR (VALN)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
VALN
Valneva SE ADR
$5.48
-3.35%
HEALTHCARE · Cap: $501.62M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 36091% more annual revenue ($56.58B vs $156.33M). NVS leads profitability with a 23.9% profit margin vs -88.3%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
VALN
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
-49.3%
Fair Value
$6.71
Current Price
$5.48
$1.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -179.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VALN
VALN has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : VALN
The primary concerns for VALN are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.73 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while VALN is a turnaround play — different risk/reward profiles.
VALN carries more volatility with a beta of 1.40 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 17/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Valneva SE ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?